We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
-8.27%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$314M
AUM Growth
-$53.5M
Cap. Flow
-$18.5M
Cap. Flow %
-5.89%
Top 10 Hldgs %
99.44%
Holding
11
New
–
Increased
6
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$3.02M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.56M
3
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$1.02M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$988K
5
ALKS icon
Alkermes
ALKS
+$140K

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$10.4M
2
UTHR icon
United Therapeutics
UTHR
+$5.08M
3
MCK icon
McKesson
MCK
+$4.57M
4
BIIB icon
Biogen
BIIB
+$3.98M
5
ANAB icon
AnaptysBio
ANAB
+$1.19M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
1
Regeneron Pharmaceuticals
REGN
$78.5B
$46M 14.66%
82,258
+2,567
+3% +$1.56M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$45.4M 14.45%
396,575
-96,595
-20% -$10.4M
UTHR icon
3
United Therapeutics
UTHR
$25.8B
$43M 13.71%
426,215
-46,333
-10% -$5.08M
BIIB icon
4
Biogen
BIIB
$30B
$38.9M 12.39%
137,163
-14,257
-9% -$3.98M
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$366M
$37.8M 12.03%
825,329
+62,226
+8% +$3.02M
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$29.5M 9.38%
537,378
+15,871
+3% +$988K
MCK icon
7
McKesson
MCK
$100B
$27.7M 8.82%
186,030
-30,112
-14% -$4.57M
ALKS icon
8
Alkermes
ALKS
$8.22B
$26.1M 8.3%
1,572,395
+7,730
+0.5% +$140K
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$11.3M 3.6%
208,374
+13,322
+7% +$1.02M
IVC
10
DELISTED
Invacare Corporation
IVC
$6.63M 2.11%
880,920
+4,499
+0.5% +$31.2K
ANAB icon
11
AnaptysBio
ANAB
$1.58B
$1.75M 0.56%
118,858
-65,988
-36% -$1.19M

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Krensavage Asset Management held 11 positions worth $314M, down 15% from $368M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Krensavage Asset Management withdrew a net $18.5M in Q3 2020, reducing 5 holdings. Its largest reduction was Alexion Pharmaceuticals, cutting an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, Krensavage Asset Management added an estimated $3.02M to Enanta Pharmaceuticals.

  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q3 2020, an estimated $3.02M increase.
  • Krensavage Asset Management's biggest Q3 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $10.4M.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $314M portfolio in Q3 2020.
  • Krensavage Asset Management opened 0 new positions and closed 0 in Q3 2020.
  • Krensavage Asset Management's portfolio value fell 15% quarter-over-quarter to $314M.

Based on Krensavage Asset Management's 13F filing for Q3 2020, filed 17 Nov 2020.